

2024 Regular Session

HOUSE BILL NO. 204

BY REPRESENTATIVES TURNER AND CHASSION

1 AN ACT

2 To amend and reenact R.S. 40:964(Schedule I)(F)(5), (6), and (26) and to enact R.S.
3 40:964(Schedule I)(A)(101) through (105), (C)(69) through (72), (D)(8) through
4 (10), and (F)(30) and (Schedule IV)(B)(59), relative to naming language and the
5 composition of various schedules of controlled substances; and to provide for related
6 matters.

7 Be it enacted by the Legislature of Louisiana:

8 Section 1. R.S. 40:964(Schedule I)(F)(5), (6), and (26) are hereby amended and
9 reenacted and R.S. 40:964(Schedule I)(A)(101) through (105), (C)(69) through (72), (D)(8)
10 through (10), and (F)(30) and (Schedule IV)(B)(59) are hereby enacted to read as follows:

11 §964. Composition of schedules

12 Schedules I, II, III, IV, and V shall, unless and until added pursuant to R.S.
13 40:962, consist of the following drugs or other substances, by whatever official
14 name, common or usual name, chemical name, or brand name designated:

15 SCHEDULE I

16 A. Opiates. Unless specifically excepted or unless listed in another schedule,
17 any of the following opiates, including their isomers, esters, ethers, salts, or salts of
18 isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers,
19 or salts is possible within the specific chemical designation:

20 * * *

21 (101) 2',5'-dimethoxyfentanyl (N-(1-(2,5-dimethoxyphenethyl)piperidine-
22 4-yl)-N-phenylpropionamide)

23 (102) alpha'-methyl butyryl fentanyl (2-methyl-N-(1-phenethylpiperidin-4-yl)
24 -N-phenylbutanamide)

1 F. Synthetic cannabinoids. Unless specifically excepted, or contained within
 2 a pharmaceutical product approved by the United States Food and Drug
 3 Administration, or unless listed in another schedule, any material, compound,
 4 mixture, or preparation which contains any quantity of a synthetic cannabinoid found
 5 to be in any of the following individual compounds or chemical groups, or any of
 6 those individual compounds or groups which contain any synthetic cannabinoid salts,
 7 isomers, salts of isomers, or nitrogen-heterocyclic analogs, whenever the existence
 8 of such salts, isomers, salts of isomers, or nitrogen-heterocyclic analogs is possible
 9 within the specific compounds or chemical groups:

10 * * *

11 (5) Butaldehydeamidoindoles: Any compound containing a
 12 N-(1-oxobutan-2yl)-1H-indole-3-carboxamide structure, with or without substitution
 13 on the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl halide,
 14 ~~arylhalkylhalide~~ alkylarylhalide, cycloalkylmethyl, cycloalkylethyl, alkenyl,
 15 haloalkenyl, aliphatic alcohol, hydroxyl, halide, morpholinoethyl,
 16 alkylmorpholinomethyl, alkylpiperidinylmethyl or a tetrahydropyranylmethyl group,
 17 whether or not further substituted on the butaldehyde group to any extent.

18 (6) Cumylindolecarboxamides: Any compound containing a
 19 N-(2-phenylpropane-2-yl)-1H-indole-3-carboxamide structure, with or without
 20 substitution on the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl
 21 halide, ~~arylhalkylhalide~~ alkylarylhalide, cycloalkylmethyl, cycloalkylethyl, alkenyl,
 22 haloalkenyl, aliphatic alcohol, hydroxyl, halide, morpholinoethyl,
 23 alkylmorpholinomethyl, alkylpiperidinylmethyl or a tetrahydropyranylmethyl group,
 24 whether or not further substituted on the phenyl group to any extent.

25 * * *

26 (26) Phenylpropionaldehydeamidoindoles: Any compound containing a
 27 N-(1-oxo-3-phenylpropan-2yl)-1H-indole-3-carboxamide structure, with or without
 28 substitution on the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl
 29 halide, ~~arylhalkylhalide~~ alkylarylhalide, cycloalkylmethyl, cycloalkylethyl, alkenyl,
 30 haloalkenyl, aliphatic alcohol, hydroxyl, halide, morpholinoethyl,

1 alkylmorpholinomethyl, alkylpiperidinylmethyl or a tetrahydropyranylmethyl group,
2 whether or not further substituted on the phenylpropionaldehyde group to any extent.

3 * * *

4 (30) 5-Pentyl-2-(2-phenylpropan-2-yl)pyrido[4,3-b]indole-1-one

5 [Cumyl-Pegaclone; SGT-151]

6 * * *

7 SCHEDULE IV

8 * * *

9 B. Depressants. Unless specifically excepted or unless listed in another
10 schedule, any material, compound, mixture, or preparation containing any quantity
11 of the following substances, including its salts, isomers, and salts of isomers,
12 whenever the existence of such salts, isomers, and salts of isomers is possible within
13 the specific chemical designation:

14 * * *

15 (59) Zuranolone

16 * * *

17 Section 2. The Louisiana State Law Institute is hereby authorized and directed to
18 renumber the new entries to ensure that the substances are in alphabetical order.

SPEAKER OF THE HOUSE OF REPRESENTATIVES

PRESIDENT OF THE SENATE

GOVERNOR OF THE STATE OF LOUISIANA

APPROVED: _____